8-K: Kyverna KYV-101 Shows Strong gMG Phase 2 Data

Kyverna Therapeutics announced positive interim Phase 2 data for its KYV-101 therapy in generalized myasthenia gravis, demonstrating 100% clinically meaningful responses.

Summary

• Positive interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis (gMG) were announced.
• 100% of patients (6/6) achieved clinically meaningful responses in both Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, which are co-primary endpoints for the Phase 3 trial.
• Mean reductions were -8.0 points in MG-ADL and -7.7 points in QMG at 24 weeks, with rapid responses observed as early as two weeks.
• Two out of three patients with at least 24 weeks of follow-up achieved minimal symptom expression (MG-ADL score of 0 or 1).
• KYV-101 was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed.
• One patient experienced Grade 4 neutropenia, an expected adverse event, which resolved to Grade 1 with standard supportive care.
• All patients were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn and complement inhibitors up to 24 weeks post-single dose.

Sentiment

Score: 9

Explanation: The interim Phase 2 data for KYV-101 in gMG are overwhelmingly positive, showing 100% clinically meaningful responses, significant symptom reduction, and a favorable safety profile. The results are described as 'unprecedented' and 'setting a new standard,' reinforcing confidence in the Phase 3 trial and the company's broader neuroimmunology franchise potential. The only minor negative is the small patient cohort, which is typical for early-stage data.

Positives

• 100% of patients (6/6) achieved clinically meaningful responses in MG-ADL and QMG scores, the co-primary endpoints of the Phase 3 trial.
• Mean reductions of -8.0 points in MG-ADL and -7.7 points in QMG were observed at 24 weeks, indicating robust and sustained efficacy.
• Deep responses were seen rapidly, as early as two weeks post-treatment.
• Two out of three patients with at least 24 weeks of follow-up achieved minimal symptom expression (MG-ADL score of 0 or 1), suggesting potential for symptom-free states.
• KYV-101 demonstrated a favorable safety profile with no high-grade CRS and no ICANS events.
• All patients were able to discontinue background immunosuppressant therapies (nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors) up to 24 weeks after a single dose.
• The positive interim data increases confidence in the registrational KYSA-6 Phase 3 trial design and powering.

Negatives

• One patient experienced a serious adverse event of Grade 4 neutropenia, though it was an expected event and improved with supportive care.
• The Phase 2 data is from a small cohort of six patients, which limits generalizability until larger Phase 3 results are available.

Risks

• Results from prior clinical trials, named-patient access activities, and preclinical studies may not necessarily be predictive of future results.
• Uncertainties related to market conditions.
• Intellectual property rights.
• Other factors discussed in Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Kyverna Therapeutics plans to initiate enrollment for the Phase 3 portion of the registrational KYSA-6 trial by the end of 2025 and expects to share updated Phase 2 data in 2026. The company aims to deliver a first-in-class neuroimmunology franchise and is advancing KYV-101 in other autoimmune indications like stiff person syndrome and lupus nephritis, while also exploring next-generation CAR T-cell therapies.

Management Comments

• "With today's results, we are setting a new standard across key clinical outcome measures for gMG, particularly in the depth and durability of response achieved with just a single dose of KYV-101." Warner Biddle, CEO.
• "Patients experienced rapid and unprecedented symptom improvement without the need for ongoing background therapy." Warner Biddle, CEO.
• "These compelling data build upon our previously reported compassionate use experience, further advancing our goal to deliver durable, drug-free, disease-free remission, and importantly, reinforce our confidence in the KYSA-6 Phase 3 trial design." Warner Biddle, CEO.
• "With all patients exceeding the thresholds for our Phase 3 co-primary endpoints, we believe the data further validate the powering and overall design of our Phase 3 superiority trial." Naji Gehchan, M.D., Chief Medical and Development Officer.
• "KYV-101 can target gMG upstream at the disease source, through deep, tissue-based B-cell depletion. This is likely a prerequisite to an immune reset, representing a potentially significant treatment advance in gMG." Professor Srikanth Muppidi, M.D.

Industry Context

Generalized myasthenia gravis (gMG) remains a disease with significant unmet needs, as many patients continue to experience disease burden despite available treatments. Current novel therapies often require frequent, chronic dosing and do not consistently achieve a symptom-free state. KYV-101's potential to offer durable, drug-free, disease-free remission with a single dose, by targeting B-cell depletion, positions it as a potentially transformative treatment that could set a new standard in the gMG therapeutic landscape.

Comparison to Industry Standards

• Current novel therapies for gMG often require frequent and chronic dosing, whereas KYV-101 demonstrated significant improvements with a single dose.
• Existing treatments frequently fail to provide a symptom-free state, while KYV-101 achieved minimal symptom expression (MG-ADL score of 0 or 1) in two out of three patients with sufficient follow-up.
• KYV-101's mechanism of deep, tissue-based B-cell depletion is highlighted as a potential "immune reset," which could be a significant advance compared to symptomatic or less targeted treatments.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data, increasing confidence in KYV-101's market potential and the company's valuation.
• Patients with gMG: Significant positive impact, as KYV-101 offers the potential for durable, drug-free, disease-free remission with a single dose, addressing unmet needs for more effective and less burdensome treatments.
• Healthcare Providers: Provides a promising new therapeutic option for gMG patients who have failed existing therapies, potentially simplifying treatment regimens.
• Competitors: May face increased pressure to innovate or demonstrate superior efficacy/safety profiles for their gMG treatments.

Next Steps

• Initiate enrollment for the Phase 3 portion of the registrational KYSA-6 trial by the end of 2025.
• Share updated data from the Phase 2 portion of the KYSA-6 trial in 2026.
• Continue advancing KYV-101 through late-stage clinical development for stiff person syndrome and lupus nephritis.
• Utilize other KYSA trials and investigator-initiated trials (e.g., multiple sclerosis, rheumatoid arthritis) to identify future priority indications.
• Develop next-generation CAR T-cell therapies, including KYV-102, for broader autoimmune indications.

Key Dates

Recommendation

The interim Phase 2 data for KYV-101 in generalized myasthenia gravis are exceptionally strong, demonstrating 100% clinically meaningful responses and significant symptom reduction with a favorable safety profile. Management's statements suggest these results are 'unprecedented' and 'set a new standard' for gMG treatment, validating the Phase 3 trial design. The potential for durable, drug-free remission with a single dose addresses a major unmet need in a chronic disease, positioning KYV-101 as a potential best-in-class therapy. While it's interim data from a small cohort, the consistency and magnitude of the results, coupled with the clear path to Phase 3 enrollment by year-end, indicate a high probability of future success and significant market opportunity. This positive clinical de-risking event warrants a strong buy recommendation for long-term investors.

Keywords

Kyverna Therapeutics, KYTX, KYV-101, Generalized Myasthenia Gravis, gMG, CAR T-cell therapy, Autoimmune diseases, Clinical trial, Phase 2 data, Neurology, Biopharmaceutical, Cell therapy, MG-ADL, QMG, AANEM